| 摘要 |
<p>Preparations to be administered for treating or preventing ischemic diseases or arterial diseases which contain hepatocyte growth factor (HGF) as the active ingredient. Compared with intravenous administration, these preparations are advantageous in that the HGF concentration can be maintained at the affected part to which HGF has been administered and thus the half-life can be prolonged and the administration dose can be reduced; and they exert the effect almost exclusively on the affected part.</p> |
